Brief: Mateon announces presentation of oxi4503 AML study data

Oncotelic Therapeutics

06/12/2016 12:09

Dec 6 (Reuters) - Mateon Therapeutics Inc  MATN.O  - 
    * Mateon announces presentation of oxi4503 AML study data 
    * Completed enrollment in two lowest dose cohorts, third 
cohort now in progress 
    * oxi4503 was generally well tolerated in first two cohorts 
of study 
    * Across first two cohorts, 20 pct of patients achieved a 
complete remission 
    * A patient in 3.75 mg/m(2 )cohort faced dose-limiting 
toxicity of hypofibrinogenemia with no evidence of bleeding, 
which resolved with drug 
 
Source text for Eikon:  ID:nGNXNNJHCa  
Further company coverage:  MATN.O  
 
 ((bangalore.newsroom@thomsonreuters.com))